Emergent BioSolutions shares rose after the company disclosed that it will supply additional doses of CNJ-016, a treatment ...

The CDK2 inhibitor INCB123667 showed positive efficacy and safety signals in platinum-resistant/refractory ovarian cancer.

About an hour after the closing bell, shares of Emergent were trading 6.4% higher, at $7.31. The company's shares ended the day's regular session at $6.87, a gain of 3.7%.

Emergent also secured a $62.4 million contract modification for its botulism antitoxin with the U.S. Department of Health and Human Services, reinforcing its role in medical countermeasures.

Olorofim, a novel antifungal agent, shows efficacy and tolerability in patients with invasive fungal diseases with limited ...

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

Rentosertib, an AI-generated small molecule targeting Traf2- and Nck-interacting kinase, was safe and improved FVC in ...

A phase 2 trial reveals that combining intratumoral BO-112 with pembrolizumab shows potential in treating anti–PD-1-resistant ...